Tavistock Life Sciences Co. (Inve.. recently announced the acquisition of new stake in Amarin Corporation plc (NASDAQ:AMRN). The institutional investor has increased its shareholding in the Healthcare company by 211.11% to 7.0 million shares with purchase of 4.75 million shares. This fresh investment now brings its stake to 1.82% valued currently at $45.36 million. In addition, D. E. Shaw & Co. LP raised its holdings by 5.62 million to 5.7 million shares. And Federated Global Investment Manag.. has lifted its position by 54.07% or 1.86 million shares – to 5.3 million shares.
With over 7.73 million Amarin Corporation plc (AMRN) shares trading Friday and a closing price of $7.36 on the day, the dollar volume was approximately $56.87 million. The shares have shown a positive weekly performance of 6.51% and its price on 08/28/20 lost nearly -3.66%. Currently, there are 384.66M common shares owned by the public and among those 375.84M shares have been available to trade.
An analysis of what Wall Street brokers have to say about the expected price targets for this stock gives us this picture: 12 analysts who have offered their price forecasts for AMRN have a consensus price objective of $13.80. The analysts have set the share’s price value over the next 12 months at a high of $35.00 and a low of $8.00 should the stock experience a downside. Incidentally, analysts’ outlook for the Amarin Corporation plc stock is 2.20 for the next 12 months. But an upside of 78.97% will see the stock hit the forecast high price target while mean target price for the stock is $10.50.
Insiders at the company have transacted a total of 5 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 3 of these insider trades were purchases, accounting for 9,454 shares. Insider sales of the common stock occurred on 2 occasions, with total insider shares sold totaling 7,906 shares.
The top 3 mutual fund holders in Amarin Corporation plc are Artisan International Fund, iShares NASDAQ Biotechnology ETF, and Federated Hermes Kaufmann Small C. Artisan International Fund owns 6.47 million shares of the company’s stock, all valued at over $41.92 million. The company sold -0.15 million shares recently to bring their total holdings to about 1.68% of the shares outstanding. iShares NASDAQ Biotechnology ETF sold 28611.0 shares to see its total holdings shrink to 3.71 million shares valued at over $24.04 million and representing 0.96% of the shares outstanding. Federated Hermes Kaufmann Small C bought 1.86 million shares to bring its total holdings to over 3.5 million shares at a value of $22.68 million. Federated Hermes Kaufmann Small C now owns shares totaling to 0.91% of the shares outstanding.
Shares of Amarin Corporation plc (NASDAQ: AMRN) opened at $7.703, up $0.06 from a prior closing price of $7.64. However, the script later closed the day at $7.36, down -3.66%. The company’s stock has a 5-day price change of 6.51% and 9.69% over the past three months. AMRN shares are trading -65.67% year to date (YTD), with the 12-month market performance down to -51.16% lower. It has a 12-month low price of $3.95 and touched a high of $26.12 over the same period. Currently, 7.73 million shares have been traded, compared to an average intraday trading volume of 5.79 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 6.90%, 8.14%, and -40.56% respectively.
Institutional ownership of Amarin Corporation plc (NASDAQ: AMRN) shares accounts for 44.00% of the company’s 384.66M shares outstanding. Mutual fund holders own 29.03%, while other institutional holders and individual stakeholders account for 3.12% and 12.90% respectively.
It has a market capitalization of $2.95B and a beta (3y monthly) value of 2.66. The earnings-per-share (ttm) stands at -$0.04. Price movements for the stock have been influenced by the stock’s volatility, which stands at 6.44% over the week and 5.23% over the month.
Analysts forecast that Amarin Corporation plc (AMRN) will achieve an EPS of $0.01 for the current quarter, $0.02 for the next quarter and $0.48 for 2021. The lowest estimate earnings-per-share for the quarter is -$0.04 while analysts give the company a high EPS estimate of $0.04. Comparatively, EPS for the current quarter was -$0.01 a year ago. Earnings per share for the fiscal year are expected to increase by 83.10%, and 4900.00% over the next financial year. EPS should grow at an annualized rate of 42.30% over the next five years, compared to 27.30% over the past 5-year period.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 12 brokerage firm advisors rate Amarin Corporation plc (AMRN) as a “Moderate Buy” at a consensus score of 2.20. Specifically, 8 Wall Street analysts polled rate the stock as a buy, while 4 of the 12 advise that investors “hold,” and 0 rated it as a “Sell.”
Looking at the support for the AMRN, a number of firms have released research notes about the stock. Piper Sandler stated their Overweight rating for the stock in a research note on August 26, 2020, with the firm’s price target at $21. Northland Capital coverage for the Amarin Corporation plc (AMRN) stock in a research note released on May 05, 2020 offered a Outperform rating with a price target of $15. Oppenheimer was of a view on March 31, 2020 that the stock is Perform, while Jefferies gave the stock Hold rating on March 31, 2020, issuing a price target of $30- $4. Goldman on their part issued Neutral rating on March 31, 2020.